Previous studies have shown that targeting SAMHD1 can enhances the efficacy of ara-C treatment in AML by lowering dNTP levels, which in turn sensitizes AML cells to chemotherapy.32,65,66 Our study demonstrated that HSP90 inhibitors synergize with ara-C, not only in vitro but also in orthotopic and heterotopic AML mouse models in vivo. The gene discussed is SAMHD1; the disease is acute myeloid leukemia.